爱美医疗 FOLD 深 沪
交易中 09-22 10:49:44 美东时间
8.385
+0.055
+0.66%
华盛通- 最 高8.44
- 今 开8.29
- 成交量 39.94万股
- 最 低 8.22
- 昨 收 8.33
- 总市值 25.83亿
- 52周最高 12.65
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 5.51
- 委 比 -23.78%
- 总股本 3.08亿
- 历史最高 25.39
- 量 比 0.31
- 振 幅 2.64%
- 历史最低 1.765
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-18 19:23
Needham Upgrades Amicus Therapeutics to Buy, Announces $14 Price Target
Needham analyst Gil Blum upgrades Amicus Therapeutics (NASDAQ:FOLD) from Hold to Buy and announces $14 price target.
09-18 18:00
Amicus Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-18 17:57
Analysts Offer Insights on Healthcare Companies: Amicus (FOLD) and Protara Therapeutics (TARA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-17 16:50
Amicus Therapeutics Reports 4-Year Muscle Function And Biomarker Data From PROPEL Study Of Cipaglucosidase Alfa + Miglustat In Late-Onset Pompe Disease
Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga +
09-08 21:05
仅一名员工，融资5.4亿
“核药”站上了风口。 作者丨王满华 来源丨投中网 一家创业公司想要获得上亿融资，其团队规模的下限是多少？来自挪威的Actithera给出了答案：一名员工足...
08-12 15:00
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, partic...
08-06 20:30
Amicus Therapeutics Affirms FY2025 Sales Guidance of $607.539M-$644.520M vs $620.675M Est
2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22% Galafold Revenue Growth110% to 15% Pombiliti + Opfolda Revenue Growth150% to 65% Gross
07-31 19:14
Amicus Therapeutics Q2 Adj. EPS $0.01 Beats $(0.11) Estimate, Sales $154.688M Beat $147.399M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 83.33 percent decrease over earnings of $0.06 per share
07-31 19:06
